The biosensors market APAC is expected grow at a high rate between 2017 and 2022. The other major factors contributing to the growth of the biosensors market in APAC include the development of healthcare systems and increasing number of lifestyle diseases in the region. APAC is the amalgamation of some of the leading markets such as China, Japan, and India. The growth of the biosensors market in APAC for POC applications can be attributed to the huge population base, increasing investments in the healthcare sector, growing focus of key industry players on technological advancements, and significant R&D pertaining to biosensors. In September 2017, PatientSafe Solutions (US) garnered strategic investments of around USD 27 billion from EDBI. This fund was used to augment the expansion of PatientSafe’s PatientTouch System, a POC mobile solution, in APAC.
For Sample Copy Of this report: https://goo.gl/eqJ4bK
“North America is the major market for biosensors.”
North America is likely to hold the largest share of the overall biosensors market in 2017. POC diagnostics is the fastest-growing applications for biosensors in North America. The main reason behind the growth of the POC segment is the increase in addressable patient population base. According to the American Medical Association and American Medical Group Association, more than 50% Americans were living with one or more chronic disease(s) till 2012. The number of Americans suffering from chronic diseases was around 125 billion in 2000, which is expected to reach around 157 billion by 2022. The baby boomer population is witnessing a growth in incidences of chronic and infectious diseases, According to the US Census Bureau, the number of individuals over the age of 65 was 39.6 billion in 2009, which is expected to increase to 72.1 billion by 2030.
For More Information Ask Your Queries: https://goo.gl/7Pf4RQ
The biosensors market is expected to grow at a CAGR of +8% between 2017 and 2022 to reach USD 27.06 billion by 2022 from USD 15.96 billion in 2016. Glucose monitoring devices are gaining traction due to increasing incidences and prevalence of lifestyle diseases, such as diabetes, that require regular monitoring. Moreover, the proven efficacy of such testing kits has resulted in their growing adoption by doctors. According to International Diabetes Federation, the number of people suffering from diabetes is expected to grow from 415 million in 2015 to almost 642 million by 2040 worldwide.
The report also profiles the key players in the biosensors market and analyzes their market ranking. The prominent players profiled in this report are Abbott Point of Care Inc. (US), Medtronic, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Siemens AG (Germany), LifeScan, Inc. (US), LifeSensors Inc. (US), Nova Biomedical Corp. (US), Acon Laboratories Inc. (US), Universal Biosensors (Australia), Pharmaco-Kinesis Corporation (PKC) (US), Bayer Healthcare AG (Germany), Biacore (UK), Bio-Rad Laboratories Inc. (US), Biosensors International Ltd.(Singapore), Ercon, Inc. (US), DuPont (US), and Sysmex Corporation (Japan).
This research report categorizes the biosensors market on the basis of application, technology, product, and geography. The report also provides the Porter’s five forces analysis, along with a description of each of its forces and their respective impact on the biosensors market; description of major drivers, restraints, challenges, and opportunities pertaining to the market; value chain analysis; and market ranking analysis.